secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2026-07-07T12:15:15+00:00
Accession:  0001193125-26-296936
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Breakthrough T1D awards grant for SAB-142 study in Stage 3 T1D beyond 100 days
------------------------------------------------------------------------------

- Breakthrough T1D awarded grant to Dr. Michael Haller (U. Florida) for PRISE-hATG study of SAB-142 in Stage 3 T1D patients 100 days to 2 years from diagnosis.
- Study aims to assess SAB-142's ability to preserve C-peptide and modulate immune responses in patients with residual beta cell function beyond 100 days.
- SAB BIO will co-fund the study; it complements ongoing Phase 2b SAFEGUARD trial in new onset Stage 3 T1D.
- CEO Samuel Reich says SAB-142 has potential as best-in-class disease-modifying therapy for T1D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526296936/0001193125-26-296936-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000119312526296936/sabs-20260707.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-296936

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer